Trilafon

Depression, Generalized Anxiety Disorder, Schizophrenia + 8 more

Treatment

12 FDA approvals

20 Active Studies for Trilafon

What is Trilafon

Perphenazine

The Generic name of this drug

Treatment Summary

A medication used to treat mental health disorders, similar to the effects of chlorpromazine.

Perphenazine

is the brand name

image of different drug pills on a surface

Trilafon Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Perphenazine

Perphenazine

1987

153

Approved as Treatment by the FDA

Perphenazine, also known as Perphenazine, is approved by the FDA for 12 uses like Anxiety and Generalized Anxiety Disorder .

Anxiety

Used to treat severe Anxiety in combination with Amitriptyline

Generalized Anxiety Disorder

Used to treat Anxiety in combination with Amitriptyline

Mental Depression

Used to treat moderate Depressed mood in combination with Amitriptyline

Depression

Used to treat Depression in combination with Amitriptyline

Mental Depression

Used to treat severe Depressed mood in combination with Amitriptyline

severe Nausea and vomiting

moderate Anxiety

Used to treat moderate Anxiety in combination with Amitriptyline

Schizophrenia

Helps manage Schizophrenia

Chronic Physical Illness

Used to treat Chronic Physical Illness in combination with Amitriptyline

Nausea

severe agitation

Used to treat severe agitation in combination with Amitriptyline

moderate Agitation

Used to treat moderate Agitation in combination with Amitriptyline

Effectiveness

How Trilafon Affects Patients

Perphenazine is a powerful medication used to treat psychiatric disorders. It belongs to a class of drugs called phenothiazines, which block the chemical dopamine in the brain. Perphenazine is 10-15 times stronger than other phenothiazine drugs and is just as effective as haloperidol in treating symptoms, but may cause similar early and late side effects.

How Trilafon works in the body

Perphenazine works by blocking the activity of dopamine receptors, which are responsible for sending signals to the vomiting center in the brain. It also binds to alpha-adrenergic receptors and stops them from sending messages that could lead to nausea and vomiting.

When to interrupt dosage

The prescribed measure of Trilafon is contingent upon the diagnosed ailment, including Generalized Anxiety Disorder, moderate Agitation and Depression. The amount of dosage is contingent upon the administration technique (e.g. Syrup - Oral or Tablet, sugar coated - Oral) outlined in the accompanying table.

Condition

Dosage

Administration

Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Nausea

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Chronic Physical Illness

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Generalized Anxiety Disorder

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Schizophrenia

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

severe agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Warnings

Trilafon Contraindications

Condition

Risk Level

Notes

large dose of CNS depressants

Do Not Combine

Brain Injuries

Do Not Combine

Liver Damage

Do Not Combine

Coma

Do Not Combine

Disease

Do Not Combine

greatly obtunded patients

Do Not Combine

Bone Marrow

Do Not Combine

There are 20 known major drug interactions with Trilafon.

Common Trilafon Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Perphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Perphenazine.

Azelastine

Major

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Perphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.

Trilafon Toxicity & Overdose Risk

Signs of an overdose of this drug include confusion and unconsciousness, and children may have seizures. It may take up to 48 hours for symptoms to become noticeable. Tests in rats and mice show that the lowest toxic dose is 318 mg/kg and 64 mg/kg, respectively.

image of a doctor in a lab doing drug, clinical research

Trilafon Novel Uses: Which Conditions Have a Clinical Trial Featuring Trilafon?

At present, 985 active clinical trials are investigating the potential of Trilafon to alleviate moderate Agitation, Anxiety and Nausea.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

moderate Anxiety

0 Actively Recruiting

Nausea

0 Actively Recruiting

Anxiety

0 Actively Recruiting

moderate Agitation

0 Actively Recruiting

Chronic Physical Illness

1 Actively Recruiting

Not Applicable

severe agitation

0 Actively Recruiting

Depression

304 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Mental Depression

0 Actively Recruiting

Mental Depression

0 Actively Recruiting

Trilafon Reviews: What are patients saying about Trilafon?

5

Patient Review

9/25/2009

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

TARDIVE DYSKINESIA

5

Patient Review

3/24/2010

Trilafon for Schizophrenia

I've tried a lot of different antipsychotics, and this is the first one that's both effective and doesn't have too many side effects.

5

Patient Review

11/26/2010

Trilafon for Schizophrenia

I've tried other medications in the same class as Trilafon, and this one is by far the most effective with the least amount of side effects.

4.7

Patient Review

5/7/2010

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I have bipolar disorder, ADHD, and severe anxiety disorder. I've been on Trilafon for a little while now and it's really helped to stabilize my moods. Much better than any other medication I've tried in the past.

4.7

Patient Review

4/10/2010

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I initially forgot to take this medication, but I was really pleased with how it curbed my appetite. I didn't feel the need to overeat anymore.

4

Patient Review

7/14/2010

Trilafon for Schizophrenia

I felt more focused and energetic, with fewer racing thoughts.

4

Patient Review

6/2/2009

Trilafon for Schizophrenia

3.7

Patient Review

5/14/2013

Trilafon for Schizophrenia

This medication was highly effective at removing my positive symptoms of schizophrenia. However, I developed abnormal mouth and tongue movements as a result. These movements have continued even after going off the medication, which has been since January. Therefore, I would not recommend this drug to anyone.

2.3

Patient Review

9/29/2012

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I was prescribed this medication after being misdiagnosed while in foster care. Even though it's been three years since I stopped taking the medicine, I continue to suffer from a variety of side effects, including sun sensitivity, irregular periods, an irregular heartbeat, sexual problems and eye twitches.

1

Patient Review

2/15/2012

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

This treatment made me feel really out of it and not in a good way.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trilafon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does perphenazine do to your brain?

"Perphenazine is a type of medication known as a conventional antipsychotic. It works by reducing abnormal excitement in the brain."

Answered by AI

How long does it take for Trilafon to work?

"It may take as much as 4-6 weeks of regular use to see the full benefit of the medication, even though you may notice some effects soon after starting."

Answered by AI

Is Trilafon still available?

"The drug Trilafon is no longer being manufactured in the United States, but similar drugs may still be available. Trilafon was an antipsychotic drug used to treat schizophrenia. It belonged to a class of drugs called phenothiazines."

Answered by AI

What is Trilafon used for?

"Aripiprazole works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain.

Aripiprazole is a medication used to treat certain mental disorders such as schizophrenia and bipolar disorder. This medicine helps the patient to think more clearly and take part in everyday life. It can reduce aggressive behavior and the desire to hurt oneself or others. Aripiprazole works by restoring the balance of certain neurotransmitters in the brain."

Answered by AI

Clinical Trials for Trilafon

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials
Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials